secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001157523-24-000165
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q4 revenue $902M (+9%); FY24 guides $3.93-4.04B, EPS $10.84-11.33
-----------------------------------------------------------------------

- Q4 revenue $902M, up 9% reported and 8% organic; CAG Diagnostics recurring revenue +11% reported and +10% organic.
- Q4 EPS $2.32, up 13% reported and 17% on a comparable basis; full-year EPS $10.06 (+25% reported).
- FY24 revenue guidance $3.93B-$4.04B (+7.5%-10.5% reported); EPS $10.84-$11.33 (+8%-13% comparable).
- Full-year operating margin expanded 330 bps reported; FY24 operating margin target 30.2%-30.7%.
- New IDEXX inVue Dx slide-free cellular analyzer launch targeted for late 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/0001157523-24-000165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/a53891750.htm
  HTML page:      https://secwatch.observer/filing/0001157523-24-000165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer